These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33861387)

  • 1. Casimersen: First Approval.
    Shirley M
    Drugs; 2021 May; 81(7):875-879. PubMed ID: 33861387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Casimersen (AMONDYS 45™): An Antisense Oligonucleotide for Duchenne Muscular Dystrophy.
    Assefa M; Gepfert A; Zaheer M; Hum JM; Skinner BW
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Casimersen for Duchenne muscular dystrophy.
    Wilton-Clark H; Yokota T
    Drugs Today (Barc); 2021 Dec; 57(12):707-717. PubMed ID: 34909800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMONDYS 45 (Casimersen), a Novel Antisense Phosphorodiamidate Morpholino Oligomer: Clinical Considerations for Treatment in Duchenne Muscular Dystrophy.
    Vasterling ME; Maitski RJ; Davis BA; Barnes JE; Kelkar RA; Klapper RJ; Patel H; Ahmadzadeh S; Shekoohi S; Kaye AD; Varrassi G
    Cureus; 2023 Dec; 15(12):e51237. PubMed ID: 38283433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golodirsen: First Approval.
    Heo YA
    Drugs; 2020 Feb; 80(3):329-333. PubMed ID: 32026421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial.
    Wagner KR; Kuntz NL; Koenig E; East L; Upadhyay S; Han B; Shieh PB
    Muscle Nerve; 2021 Sep; 64(3):285-292. PubMed ID: 34105177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Viltolarsen: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(10):1027-1031. PubMed ID: 32519222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eteplirsen: First Global Approval.
    Syed YY
    Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
    Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
    Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA; Saito T; Duddy W; Takeda S; Yokota T
    Methods Mol Biol; 2018; 1828():141-150. PubMed ID: 30171539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
    Sheikh O; Yokota T
    Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golodirsen for Duchenne muscular dystrophy.
    Anwar S; Yokota T
    Drugs Today (Barc); 2020 Aug; 56(8):491-504. PubMed ID: 33025945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viltolarsen: From Preclinical Studies to FDA Approval.
    Roshmi RR; Yokota T
    Methods Mol Biol; 2023; 2587():31-41. PubMed ID: 36401022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casimersen (Amondys 45) for Duchenne muscular dystrophy.
    Med Lett Drugs Ther; 2021 Jun; 63(1627):e104-e105. PubMed ID: 34181634
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
    Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
    JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viltolarsen: a treatment option for Duchenne muscular dystrophy patients who are amenable to exon 53 skipping therapy.
    Czifrus E; Berlau DJ
    Expert Rev Neurother; 2023; 23(10):853-858. PubMed ID: 37572081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
    Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
    Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy.
    Watanabe N; Nagata T; Satou Y; Masuda S; Saito T; Kitagawa H; Komaki H; Takagaki K; Takeda S
    Mol Ther Nucleic Acids; 2018 Dec; 13():442-449. PubMed ID: 30388618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viltolarsen for the treatment of Duchenne muscular dystrophy.
    Roshmi RR; Yokota T
    Drugs Today (Barc); 2019 Oct; 55(10):627-639. PubMed ID: 31720560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.